Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection

Parastoo Hosseini, Hakimeh Rahimi, Mahsa Mohammadi Najafabadi, Atousa Ghorbani, Shima Karbasi Najafabadi, Arezoo Faridzadeh, Javad Arabpour, Ehsan Khormali, Niloofar Deravi


The global widespread mortality after the emergence of SARS-CoV-2 infection in China, has become a critical concern all around the world. Convalescent plasma (CP) therapy is one of the methods elevating the survival rate for COVID-19 infection cases. This technique, as a practicable therapy, was used in previous viral outbreaks including influenza, SARS and MERS. In CP therapy, the blood plasma is collected from persons rehabilitated from that specific infection in order to develop a passive immunity in other patients. Therefore, this review aimed to point out the role of CP therapy in aforementioned viral infections and illustrate different factors influencing the efficacy of CP therapy.


SARS-COV-2; Convalescent plasma therapy; COVID-19; MERS; SARS


Xu J. Evolutionary history and phylodynamics of influenza A and B neuraminidase (NA) genes inferred from large-scale sequence analyses. PLoS One. 2012; 7(7):e38665.

Plans-Rubió, P., Prevention and control of influenza in persons with chronic obstructive pulmonary disease. Int J Chronic Obstruct Pulmonary Dis. 2007;2(1):41.

Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009;459(7249):931-9.

Bosch BJ. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proceed Nat Acad Sci. 2004;101(22):8455-460.

Memish ZA. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis. 2013;19(11):1819.

Petrosillo N. COVID-19, SARS and MERS: are they closely related? Clinical Microbiology and Infection, 2020.

Mizumoto K, Kagaya K, Zarebski A. Estimating the asymptomatic proportion of 2019 novel coronavirus onboard the Princess Cruises Ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10).

COVID-19 Coronavirus Pandemic. cited on 3 February 2021. Available from:

Santos I A. Antivirals against Coronaviruses: candidate drugs for SARS-coV-2 treatment? Frontiers Microbiol. 2020;11:1818.

Cascella M. Features, evaluation and treatment coronavirus (COVID-19), in Statpearls [internet]. 2020. StatPearls Publishing.

Wong V. Treatment of severe acute respiratory syndrome with convalescent plasma. Hong Kong Med J. 2003;9(3):199-201.

Arabi Y. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. Springerplus. 2015;4(1): 1-8.

Hung IF. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011. 52(4):447-56.

Duan K. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020;117(17):9490-6.

Casadevall A, Joyner MJ, Pirofski LA. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. J Clin Invest. 2020; 130(10).

Wu R. An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Reports. 2020:1.

Barlow A. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy. J Human Pharmacol Drug Ther. 2020;40(5):416-37.

Gautret P. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrobial Agents. 2020:105949.

Li H. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020:1-9.

Peng H. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. Stem Cell Res Ther. 2020;11(1):1-6.

Chen W. Chinese herbal medicines for the treatment of type A H1N1 influenza: a systematic review of randomized controlled trials. PloS One. 2011;6(12): e28093.

Xiaoyan L. Clinical outcomes of influenza-like illness treated with Chinese herbal medicine: an observational study. J Traditional Chinese Med. 2018;38(1):107-16.

Ang L. Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines. Integrative Med Res. 2020:100407.

Cheng Y. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-6.

Khaw WSL, Makki S, Rooney KD. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a systematic review and exploratory meta-analysis. 2014.

Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. TRENDS in Immunology. 2003;24(9): 474-8.

Casadevall A, Scharff MD. Serum therapy revisited: animal models of infection and development of passive antibody therapy. Antimicrobial Agents and Chemotherapy. 1994;38(8):1695.

Van Erp EA. Fc-mediated antibody effector functions during respiratory syncytial virus infection and disease. Frontiers Immunol. 2019;10:548.

Gunn BM. A role for Fc function in therapeutic monoclonal antibody-mediated protection against Ebola virus. Cell Host Microbe. 2018;24(2):221-33. e5.

Lindholm PF, Ramsey G, Kwaan HC. Passive immunity for coronavirus disease 2019: a commentary on therapeutic aspects including convalescent plasma. in Seminars in thrombosis and hemostasis. 2020. Thieme Medical Publishers.

Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfusion Apheresis Sci. 2020:102790.

Rojas M. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmunity Rev. 2020: 102554.

Wang J. Cytokine storm and leukocyte changes in mild versus severe SARS‐CoV‐2 infection: Review of 3939 COVID‐19 patients in China and emerging pathogenesis and therapy concepts. J Leukocyte Biol. 2020;108(1):17-41.

Naeem S. Successful recovery from COVID‐19 in three kidney transplant recipients who received convalescent plasma therapy. Transplant Infect Dis. 2020:e13451.

Ahn JY. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020;35(14).

Karekadavath N. Convalescent plasma therapy in first four critically Ill COVID-19 patients in Kerala, India. Dr. Sulaiman Al Habib Med J. 2020;2(3):87-91.

Kumar N, Kumar S, Patel S. Convalescent plasma therapy in critically ill patients with late stage Covid-19. Chest. 2020;158(4):A601.

Biju MP. Convalescent plasma as a potential therapy for treating covid-19 patients. J Am Med Assoc. 2020.

Liu ST. Convalescent plasma treatment of severe COVID-19: a propensity score–matched control study. Nature Med. 2020:1-6.

Spiezia L. COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure. Thromb Haemost. 2020;120(6):998-1000.

Samad N. Convalescent plasma therapy for management of COVID-19: Perspectives and deployment in the current global pandemic. Risk Management and Healthcare Policy. 2020;13:2707.

Selvi V. Convalescent plasma: A challenging tool to treat COVID-19 patients—A lesson from the past and new perspectives. BioMed Res Int. 2020:2606058.

Hirayama F. Current understanding of allergic transfusion reactions: incidence, pathogenesis, laboratory tests, prevention and treatment. Brit J Haematol. 2013;160(4):434-44.

Soo Y. Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676-8.

Yeh KM. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrobial Chemother. 2005;56(5):919-922.

Mair-Jenkins J. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211(1):80-90.

(BRN), W.B.R.N. Position paper on collection and use of convalescent plasma or serum as an element in middle east respiratory syndrome Coronavirus response.

Arabi YM. Feasibility of using convalescent plasma immunotherapy for MERS-CoV infection, Saudi Arabia. Emerging Infect Dis. 2016;22(9):1554.

Ko JH. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018;23(7):617-22.

Xu Z. The efficacy of convalescent plasma for the treatment of severe influenza. MedRxiv, 2020.

Wong HK. Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation for influenza A (H1N1) infection. Transfusion. 2010; 50(9):1967-71.

Altuntas F, Yigenoglu TN. Convalescent plasma therapy in patients with COVID-19. Transfusion and Apheresis Science, 2020:4.

Australia JWS. Plasma therapy cured a COVID-19 patient with long duration. Med Comm. 2020:4.

Zeng H. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series. Signal Transduction Targeted Ther. 2020; 5(1):1-12.

Joyner MJ. Early safety indicators of COVID-19 convalescent plasma in 5,000 patients. J Clin Invest. 2020.

Li L. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: A randomized clinical trial. JAMA. 2020.

Full Text: PDF